業績｜論文・出版物｜目次｜ALL

ヒト腸管オルガノイドを用いた医薬品開発プラットフォーム

乾達也、水口裕之

創薬研究における細胞培養の今 (in press)

Cryopreservation of hepatocyte organoid-derived cells generated from human iPS cells.

Nagai W., Inui J., Ueyama-Toba Y., Asano R., Mizuguchi H.

Biol. Pharm. Bull., 48, 1391-1398 (2025)

Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity.

Ono R., Tokuoka S., Tachibana M., Ishii J.K., Sakurai F., Mizuguchi H.

J. ImmunoTher. Cancer, 13, e006558 (2025)

Considerations for developing CYP induction assays in hepatocytes: Insights from a multilaboratory study.

Toyoda H., Nozue A., Nishida Y., Yakabe Y., Aiki Y., Ueyama-Toba Y., Takayama K., Mizuguchi H., Mori C., Torisawa Y.S., Sakai Y., Iwao T., Matsunaga T., Horiuchi S., Yamazaki D., Ishida S., Kojima N., Inamura K., Sakai Y., Nishikawa M., Mihara I., Akabane T., Ito Y.

Eur. J. Cell Biol., 104, 151497 (2025)

An in vitro safety evaluation model for assessing the effects of a chemical drug on the human intestinal barrier integrity using genetically modified Caco-2 cells expressing drug-metabolizing enzymes.

Bai L., Sakimura S., Niwa Y., Mizuguchi H., Maeda S., Ikemura K., Okuda　M., Kondoh, M.

Toxicol. Lett., 410, 113-120 (2025)

Two-dimensionally cultured functional hepatocytes generated from human induced pluripotent stem cell-derived hepatic organoids for pharmaceutical research.

Inui J., Ueyama-Toba Y., Nagai W., Asano R., Mizuguchi H.

Biomaterials, 318, 123148 (2025)

Air-liquid interface culture alters the characteristics and functions of monolayers generated from human iPS cell‑derived enterocyte‑like cell organoids

Inui T., Uraya Y., Ueyama-Toba Y., Mizuguchi H.

Eur. J. Cell Biol., 104, 151479 (2025)

Evaluation of the correlation between nuclear localization levels and genome editing efficiencies of Cas12a fused with nuclear localization signals.

Tsukamoto T., Mizuta H., Sakai E., Sakurai F., Mizuguchi H.

J. Pharm. Sci., 114, 841-848 (2025)

Adenoviral Vector Construction II: Bacterial Systems

Hemmi M, Mizuguchi H.

Adenoviral Vectors for Gene Therapy (Third Edition), 131-148 (2025)

Approaches to the Treatment of Lifestyle-related Diseases Through the Regulation of Phospholipid Biosynthesis in the Liver

Shimizu K., Shindou H., Tomita K., Nishinaka T.

YAKUGAKU ZASSHI, 145, 171-176 (2025)

ヒト肝臓オルガノイドの創薬研究への応用

植山（鳥羽）由希子、仝嫣然、水口裕之

薬学雑誌, 145, 189-194 (2025)

ヒトiPS細胞を利用した生体模倣システムの構築と医薬品評価への応用

植山（鳥羽）由希子、水口裕之

薬剤学, 85, 55-59 (2025)

実験におけるクリーンベンチ・安全キャビネットの使い方

清水かほり

Drug Delivery System, 40, 77-79 (2025)

改良型アデノウイルスベクターを用いた肝臓内の脂質の量と種類の制御による糖尿病の遺伝子治療法の開発

清水かほり

Drug Delivery System, 40, 82-83 (2025)

肝臓内のリン脂質プロファイルに着目した、糖尿病に対する遺伝子治療法の開発

清水かほり

生産と技術, 77, 31-33 (2025)

ヒトiPS細胞由来肝オルガノイドの樹立とその二次元培養による肝細胞の成熟化

乾純平、植山（鳥羽）由希子、水口裕之

肝細胞研究会　研究交流 (2025)

Generation and application of CES1-knockout Tet-Off-regulated CYP3A4 and UGT1A1-expressing Caco-2 cells.

Murata M., Okada K., Takahashi M., Ueyama-Toba Y., Ito S., Mizuguchi H.

Toxicol Lett., 401, 158-169 (2024)

Development of a hepatic differentiation method in 2D culture from primary human hepatocyte-derived organoids for pharmaceutical research.

Ueyama-Toba Y., Tong Y., Yokota J., Murai K., Hikita H., Eguchi H., Takehara T., Mizuguchi H.

iScience, 27, 110778 (2024)

Development of a novel adenovirus serotype 35 vector vaccine possessing an RGD peptide in the fiber knob and the E4 orf 4, 6, and 6/7 regions of adenovirus serotype 5

Onishi R., Ikemoto S., Shiota A., Tsukamoto T., Asayama A., Tachibana M., Sakurai F., Mizuguchi H.

Int J Pharm., 662, 124480 (2024)

Transplacental delivery of factor IX Fc-fusion protein ameliorates bleeding phenotype of newborn hemophilia B mice

Sakurai F., Iizuka S., Tsukamoto T., Shiota A., Shimizu K., Ohashi K., Mizuguchi H.

J Control Release, 374, 415-424 (2024)

目次に戻る

大阪大学大学院薬学研究科分子生物学分野

Laboratory of Biochemistry and Molecular Biology

Graduate School of Pharmaceutical Sciences, Osaka University

業績｜論文・出版物｜目次｜ALL